Graham Capital Management L.P. boosted its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 1,643.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,162,499 shares of the company's stock after purchasing an additional 1,095,830 shares during the quarter. Graham Capital Management L.P. owned approximately 0.72% of Neumora Therapeutics worth $1,162,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in the company. Lunate Capital Ltd bought a new position in Neumora Therapeutics in the first quarter worth about $2,124,000. Northern Trust Corp increased its holdings in shares of Neumora Therapeutics by 7.7% during the fourth quarter. Northern Trust Corp now owns 734,847 shares of the company's stock valued at $7,789,000 after acquiring an additional 52,464 shares in the last quarter. Stempoint Capital LP acquired a new position in shares of Neumora Therapeutics during the fourth quarter valued at about $4,538,000. Cerity Partners LLC increased its holdings in shares of Neumora Therapeutics by 24.0% during the first quarter. Cerity Partners LLC now owns 302,505 shares of the company's stock valued at $303,000 after acquiring an additional 58,597 shares in the last quarter. Finally, Federated Hermes Inc. acquired a new position in shares of Neumora Therapeutics during the first quarter valued at about $285,000. 47.65% of the stock is currently owned by institutional investors.
Neumora Therapeutics Stock Performance
Neumora Therapeutics stock traded down $0.03 during mid-day trading on Tuesday, hitting $1.64. The company had a trading volume of 152,086 shares, compared to its average volume of 1,925,611. The company has a current ratio of 10.54, a quick ratio of 10.54 and a debt-to-equity ratio of 0.11. Neumora Therapeutics, Inc. has a 12-month low of $0.61 and a 12-month high of $17.19. The company's fifty day moving average is $1.58 and its 200-day moving average is $1.15. The company has a market capitalization of $264.79 million, a price-to-earnings ratio of -1.04 and a beta of 2.92.
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.05. Equities research analysts predict that Neumora Therapeutics, Inc. will post -1.61 EPS for the current year.
Analysts Set New Price Targets
A number of brokerages recently commented on NMRA. Needham & Company LLC reiterated a "buy" rating and issued a $5.00 target price on shares of Neumora Therapeutics in a research report on Tuesday, May 13th. Mizuho upped their target price on Neumora Therapeutics from $4.00 to $5.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. Three investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $7.14.
View Our Latest Stock Analysis on Neumora Therapeutics
About Neumora Therapeutics
(
Free Report)
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Featured Stories
Before you consider Neumora Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.
While Neumora Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
